Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Tetrahedron Lett ; 51(33): 4357-4360, 2010 Aug 14.
Article in English | MEDLINE | ID: mdl-20865132

ABSTRACT

Synthesis of nine macrocyclic peptide HDAC inhibitors and three triazole derivatives are described. HDAC inhibitory activity of these compounds against HeLa cell lysate is evaluated. The biological data demonstrates that incorporation of a triazole unit improves the HDAC inhibitory activity.

2.
Bioorg Med Chem ; 17(16): 5806-25, 2009 Aug 15.
Article in English | MEDLINE | ID: mdl-19643615

ABSTRACT

We report an extensive structure-activity relationship (SAR) of 78 compounds active against two pancreatic cancer cell lines. Our comprehensive evaluation of these compounds utilizes SAR that allow us to evaluate which features of potent compounds play a key role in their cytotoxicity. This is the first report of 19 new second-generation structures, where these new compounds were designed from the first generation of 59 compounds. These 78 structures were tested for their cytotoxicity and this is the first report of their activity against two pancreatic cancer cell lines. Our results show that out of 78 compounds, three compounds are worth pursuing as leads, as they show potency of 55% in both cancer cell lines. These three compounds all have a common structural motif, two consecutive d-amino acids and an N-methyl moiety. Further, of these three compounds, two are second-generation structures, indicating that we can incorporate and utilize data from the first generation to design potency into the second generation. Finally, one analog is in the mid nanomolar range, and has the lowest IC(50) of any reported San A derivative. These analogs share no structural homology to current pancreatic cancer drugs, and are cytotoxic at levels on par with existing drugs treating other cancers. Thus, we have established Sansalvamide A as an excellent lead for killing multiple pancreatic cancer cell lines.


Subject(s)
Antineoplastic Agents/chemistry , Depsipeptides/chemistry , Pancreatic Neoplasms/drug therapy , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/toxicity , Cell Line, Tumor , Depsipeptides/chemical synthesis , Depsipeptides/toxicity , Drug Design , Drug Resistance, Neoplasm/drug effects , Drug Screening Assays, Antitumor , Humans , Structure-Activity Relationship
3.
Bioorg Med Chem Lett ; 18(8): 2549-54, 2008 Apr 15.
Article in English | MEDLINE | ID: mdl-18381239

ABSTRACT

We outline the synthesis of six novel derivatives that are based on a recently discovered HDAC inhibitor FR235222. Our work is the first report utilizing a novel binding element, guanidine, as metal coordinators in HDAC inhibitors. Further, we demonstrate that these compounds show cytotoxicity that parallels their ability to inhibit deacetylase activity, and that the most potent compounds maintain an L-Phe at position 1, and a D-Pro at position 4. Both inhibition of HDAC activity and cytotoxicity against the pancreatic cancer cell line BxPC3 are exhibited by these compounds, establishing that a guanidine unit can be utilized successfully to inhibit HDAC activity.


Subject(s)
Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Histone Deacetylase Inhibitors , Peptides, Cyclic/chemical synthesis , Peptides, Cyclic/pharmacology , Enzyme Inhibitors/chemistry , Histone Deacetylases/metabolism , Molecular Structure , Peptides, Cyclic/chemistry , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...